Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Matthew Seymour, MD: A Clinical Trialist’s Perspective

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Jun
05
Today In Oncology
AML All-Oral Regimen Safe and Eases Treatment Administration Burden
Study Identifies Serious Infection Risks Linked to Antibody-Drug Conjugates
Overall Survival With EBRT in Hepatocellular Carcinoma
SCLC With Brain-Only Progression Original or Substitute Systemic Therapy With or Without Brain Radiotherapy
Five-Year Survival Analysis: Neoadjuvant Trastuzumab-Pertuzumab Plus Endocrine Therapy or Chemotherapy in HR-Positive/HER2-Positive Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo